VYNE Therapeutics 株価情報 (NASDAQ: VYNE)

最新ニュース VYNE Therapeutics (NASDAQ:VYNE) 株価情報

VYNE THERAPEUTICS INC

VYNE Therapeutics

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

VYNE Therapeutics Inc

President Donald Trump&#8216;s fiscal 2026 defense budget request signals a strategic pivot toward advanced missile systems and unmanned warfare capabilities while scaling back traditional fighter jet procurement, potentially reshaping revenue streams for major defense contractors.
What Happened: The $892.6 billion defense and national security budget, flat compared to fiscal 2025, cuts F-35 Lightning II orders to 47 units from the 68 requested in former President Joe Biden&#8216;s final budget proposal, Reuters reported, citing budget materials released on Wednesday by the White House.
Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), the F-35&#8217;s sole manufacturer, faces reduced near-term revenue from the program despite House appropriators proposing to increase the buy to 69 aircraft.
The budget emphasizes procurement of long-range precision munitions, including the Joint Air-to-Surface Standoff Missile Extended Range and Long Range Anti-Ship Missile, both manufactured by Lockheed Martin. These weapons systems align with Pentagon priorities for Indo-Pacific operations designed to counter Chinese military expansion.
Naval shipbuilding also faces constraints, with only three warships included in the base budget request. General Dynamics Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) and Huntington Ingalls Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>), primary builders of Virginia-class submarines and surface vessels, will see reduced procurement volumes as the Navy eliminates 7,286 civilian positions to control costs.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/46109638/microsoft-ceo-satya-nadella-praises-palantirs-fde-model-as-fantastic-insiders-say-its-not-consulting-it-builds-the-product-customers-need">Microsoft CEO Satya Nadella Praises Palantir&#8217;s FDE Model As &#8216;Fantastic&#8217;—Insiders Say It&#8217;s Not Consulting, It Builds &#8216;The Product Customers Need&#8217;</a>
Why It Matters: The budget allocates increased funding for small drone systems, reflecting lessons learned from the Ukraine conflict, where unmanned aerial vehicles proved cost-effective force multipliers. This shift <a href="https://www.benzinga.com/news/space/25/06/46090791/us-tests-radar-that-could-help-trumps-golden-dome-detect-missiles-over-1200-miles-report">benefits emerging defense technology</a> companies competing for Pentagon contracts alongside traditional prime contractors.
Trump&#8217;s Golden Dome missile defense initiative, estimated to cost over $175 billion, receives initial funding through a separate $150 billion defense package. The program has attracted interest from non-traditional defense players, including SpaceX, Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), and artificial intelligence <a href="https://www.benzinga.com/news/space/25/06/46090791/us-tests-radar-that-could-help-trumps-golden-dome-detect-missiles-over-1200-miles-report">companies seeking to disrupt</a> the established contractor base.
The budget includes a 3.8% military pay raise while retiring aging platforms to reduce operational costs, according to the report. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46106134/bernie-sanders-shares-first-thing-he-would-do-as-president-and-it-could-be-a-jab-at-elon-musk" target="_blank" rel="noreferrer noopener">Bernie Sanders Shares First Thing He Would Do As President — And It Could Be A Jab At Elon Musk</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Joey Sussman / Shutterstock.com

Politics

PLTR

Trump's Defense Budget Shifts Focus To Missiles, Drones: F-35 Orders Cut By 31%

News

GDS Holdings Unveils China REIT IPO On Shanghai Stock Exchange, With 20% Subscription From GDS And 50% Pre-placed Units

AMBO

Ambow Education Partners With University Of The West To Launch AI-Powered HybriU Platform For Global Access To U.S. Higher Education

In a significant showcase for investors, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbeonemedicines.com%2F&amp;esheet=54282398&amp;newsitemid=20250626270573&amp;lan=en-US&amp;anchor=BeOne+Medicines+Ltd.&amp;index=1&amp;md5=c3d88d2f6d71f05a0aa6c2ae0266e81c">BeOne Medicines Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>, HKEX: 06160, SSE: 688235))), a global oncology company, will announce major advancements to its industry-leading oncology pipeline during today's investor R&amp;D Day. The event comes at a pivotal moment for the Company, which has more than 40 clinical and commercial stage assets in development, a signal of both scale and ambition.
"At BeOne, our mission is simple yet bold: to create the world's first next-generation oncology company," said John V. Oyler, Co-Founder, Chairman, and CEO. "What we will unveil demonstrates our progress towards this goal today, and the promise for tomorrow. From our innovative discovery engine to one of the broadest pipelines in oncology, we are well-positioned to bring transformative medicines to patients worldwide—and to do so with speed, quality, and purpose."
BeOne's integrated, end-to-end R&amp;D model is engineered for efficiency without compromise. The Company's differentiated approach—combining in-house discovery targeting unmet patient needs, parallel early-stage exploration at low incremental cost, and rapid proof-of-concept generation—enables swift progression from bench to clinic. Our in-house manufacturing around the world, including our flagship facility in Hopewell, NJ, means we have a sustainable business model, purpose built with competitive advantages. This rigorous model has fueled a pipeline of more than 40 clinical and commercial-stage assets, making it one of the most productive in the industry. To complement this research engine, BeOne has built a robust global clinical development platform, with more than 170 trials conducted across 40 countries and more than 25,000 patients enrolled to date.
In hematologic cancers, the Company's program is driven by its wholly-owned assets including BRUKINSA&#xAE; (zanubrutinib), a second-generation covalent BTK inhibitor and the backbone of the hematology franchise, sonrotoclax, a potential best-in-class next-generation BCL2 inhibitor, and BGB-16673, a BTK CDAC. New clinical data from CaDAnCe-101 highlight the promise of BGB-16673, a potential first-in-class BTK degrader, for patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL). Meanwhile, early data show the combination of sonrotoclax and BRUKINSA has demonstrated compelling efficacy and the potential to offer a best-in-class fixed-duration treatment in CLL, setting the stage for a possible new standard of care.
In solid tumors, the Company is advancing multiple targeted modalities beyond its foundational PD-1 inhibitor TEVIMBRA&#xAE; (tislelizumab-jsgr), including CDK4 inhibitor BGB-43395, which has shown clear pharmacodynamic activity and is expected to enter registration-enabling studies for the treatment of breast cancer within the next six to 12 months.
Promising new data for the B7-H4 ADC (BG-C9074) point to a potential first-in-class therapeutic option for patients with B7-H4 expressing tumors, including those without selection criteria. Additionally, early data from the novel PRMT5 inhibitor suggest a favorable safety profile and promising efficacy, supporting its potential for differentiation in the competitive lung cancer field.

BeOne Medicines Unveils Major Advances in Oncology Pipeline During Investor R&D Day

RBC iShares Launches CAD-Hedged iShares Core S&P Total U.S. Stock Market Index ETF On TSX, Expanding Core ETF Lineup

<ul>
<li>Beam Global and the Platinum Group will form a new entity, Beam Middle East LLC, which will sell and manufacture Beam Global's patented sustainable infrastructure solutions for transportation electrification, energy storage, energy security, and smart city development across the Middle East and African regions. This joint venture supports Beam Global's strategy of geographic diversification by opening new markets and creating opportunities for revenue growth outside the United States. Beam Global, Beam Europe, and now Beam Middle East will each sell and manufacture the company's full portfolio of patented sustainable technology solutions.</li>
<li>Beam Middle East LLC will be a 50/50 joint venture between Beam Global and Platinum Group UAE, incorporated in Abu Dhabi. Beam Global will license its proprietary technologies to the joint venture and support it with incoming opportunities, training, marketing materials, and procurement assistance. Platinum Group will leverage its existing relationships at the highest levels, coordinate local sales, provide experienced and influential business development professionals, and establish manufacturing capabilities efficiently and inexpensively. Both parties will collaborate on the development of a regional manufacturing facility for the products. Beam Middle East will be headquartered in Masdar City, a pioneering sustainable urban community and world-class business and technology hub, where Platinum Group has recently signed an agreement. Masdar City is located in Abu Dhabi, the capital of the UAE, strategically positioned at the center of the country's drive toward a net-zero future by 2050.</li>
</ul>

Contracts

General

BEEM

Beam Global Enters Into A 50/50 Joint Venture Agreement With The Platinum Group, Based In The United Arab Emirates

Edgewise Therapeutics, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), a leading muscle disease biopharmaceutical company, today unveiled positive results in its sevasemten program for Becker and Duchenne muscular dystrophies.
&nbsp;
The Company announced positive data from MESA, an open label extension trial that is providing continued access to sevasemten to participants with Becker who were previously enrolled in ARCH, or completed CANYON, GRAND CANYON, or DUNE. As of the March 2025 data cut, 99% of eligible participants (n=85) are enrolled in MESA.
The MESA data demonstrated sustained disease stabilization, reinforcing prior ARCH and CANYON findings. Importantly, CANYON participants who rolled over to MESA showed increased North Star Ambulatory Assessment (NSAA) scores over 18 months (0.8 point improvement from baseline), with a trend toward improvement in placebo participants switching to sevasemten (0.2 point improvement since initiation of sevasemten). During the 18 months of sevasemten treatment, participants' NSAA scores continued to diverge relative to the expected functional declines seen in multiple Becker natural history studies. Further, NSAA scores for ARCH participants who rolled over to MESA remained stable after three years of treatment. Sevasemten continues to demonstrate a favorable safety profile after up to three years of treatment.&nbsp;

EWTX

Edgewise Therapeutics Reports Results in Sevasemten Program for Becker and Duchenne Muscular Dystrophies

Theravance Biopharma, Inc.&nbsp;("Theravance Biopharma" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) today announced that Viatris Inc. ("Viatris"), has secured regulatory approval from China's National Medical Products Administration (NMPA) for YUPELRI&#xAE; (revefenacin) inhalation solution, the first once–daily nebulized long–acting muscarinic antagonist (LAMA) approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) in China.
&nbsp;
This approval triggers a one-time $7.5 million milestone from Viatris to Theravance Biopharma, which is expected to be received in Q3 2025. Theravance Biopharma is also eligible for further sales-based milestones of up to $37.5 million and tiered royalties of 14% to 20% on net sales in China. Viatris is responsible for all aspects of development and commercialization of YUPELRI in China.
Today's announcement offers further support for Theravance Biopharma's diversified and improving financial position, which includes $131 million in cash as of March 31, 2025, an additional $225 million from the recent sale of TRELEGY royalties to GSK, 35% of U.S. YUPELRI profits, and up to $150 million in near-term potential TRELEGY milestone payments from Royalty Pharma. It also comes as the Company nears completion of enrollment in the open label portion of CYPRESS, its registrational study of ampreloxetine in symptomatic neurogenic orthostatic hypotension associated with multiple system atrophy. Ampreloxetine is a wholly-owned asset with the potential to address a significant unmet need in this rare neurological disorder.

Government

Regulations

TBPH

Theravance Biopharma Scores $7.5M Milestone After YUPELRI Inhalation Solution Approved in China for COPD Treatment

Corus Entertainment (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CJR#TSX">CJR</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.05) by 220 percent. This is a 160 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $297.806 million which missed the analyst consensus estimate of $297.850 million by 0.01 percent. This is a 10.25 percent decrease over sales of $331.804 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

TSX:CJR

TSX:CJR.B

Corus Entertainment Q3 Adj. EPS $0.06 Beats $(0.05) Estimate, Sales $297.806M Miss $297.850M Estimate

Acuity Brands Q3 Adj. EPS $5.12 Beats $4.43 Estimate, Sales $1.179B Beat $1.148B Estimate

<a target="_blank" href="https://www.benzinga.com/topic/chip-stocks" rel="noreferrer noopener">Semiconductor equipment maker</a> ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) is working to develop advanced lithography machines to serve the next-generation chip industry.
The Netherlands-based company and its exclusive optics partner Carl Zeiss are studying designs for machines that could print circuits with a&nbsp;resolution like 5 nanometers in a single exposure, Nikkei Asia <a target="_blank" href="https://asia.nikkei.com/Editor-s-Picks/Interview/ASML-commits-to-developing-even-more-advanced-chipmaking-tools" rel="noreferrer noopener">reported</a> on Thursday, citing ASML executive vice president Jos Benschop.
They expect the technology to meet the industry&#8217;s needs from 2035 and beyond.
Also Read: <a href="https://www.benzinga.com/news/global/25/05/45570606/asml-bets-big-on-high-powered-chip-tools-as-taiwan-semiconductor-intel-micron-line-up" target="_blank" rel="noreferrer noopener">ASML Bets Big On High-Powered Chip Tools As Taiwan Semiconductor, Intel, Micron Line Up</a>
Dutch giant ASML&#8217;s stock has faced significant headwinds, plunging over 27% in the last 12 months. This decline is largely attributable to mounting geopolitical tensions and pervasive macroeconomic uncertainty impacting the global technology sector.
The company has seen its market value diminish by over $130 billion within a year, primarily due to export restrictions to China imposed by the Dutch government, influenced by U.S. pressure aimed at limiting China&#8217;s access to advanced chip technology. Additionally, broader uncertainty surrounding U.S. tariffs on goods from various countries has contributed to investor apprehension.3
Consequently, multiple Wall Street firms have <a target="_blank" href="https://www.benzinga.com/quote/ASML/analyst-ratings" rel="noreferrer noopener">downgraded their ratings</a> for ASML and revised their price forecasts, reflecting concerns about the company&#8217;s immediate growth prospects given the restrictive trade environment.
Meanwhile, Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a target="_blank" href="https://www.benzinga.com/media/25/05/45653729/taiwan-semiconductor-and-intel-weigh-benefits-of-asmls-pricey-chipmaking-equipment" rel="noreferrer noopener">and other chipmakers</a> are still assessing ASML&#8217;s high numerical aperture (NA) machines for use in their most advanced nodes.
Despite the nearly $400 million price tag, almost double that of other equipment, these machines have yet to prove faster or more beneficial than existing chip fabrication tools.
In a notable development, Kevin Zhang from Taiwan Semiconductor rejected using ASML&#8217;s high-NA machines for its A16 node, citing cost concerns, and instead considered using low-NA EUV machines to achieve scaling advantages.
Conversely, Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) plans to adopt the High-NA EUV machine for its 14A process to strengthen its contract chip business and better compete with Taiwan Semiconductor. However, the company noted that customers could still opt for older, well-tested technologies.
Price Action: ASML stock concluded Wednesday&#8217;s trading session higher by 0.23%, closing at $815.24.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46105742/nvidia-supplier-taiwan-semiconductor-wants-to-raise-10-billion-for-this-risk-it-cannot-control" target="_blank" rel="noreferrer noopener">Nvidia Supplier Taiwan Semiconductor Wants To Raise $10 Billion For This Risk It Cannot Control</a></li>
</ul>
Image via Shutterstock

Tech

Media

ASML

INTC

Dutch Giant ASML Unveils Plans For Next-Gen Chip Tech

Trump's 'Big Beautiful Bill' To Inject $150 Billion Into Immigration Enforcement Over The Next Four Years: Report

Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) CEO Andy Jassy&#8216;s recent announcement that artificial intelligence will shrink the company&#8217;s corporate workforce has prompted a stark warning from former Amazon Vice President Ethan Evans, who says employees must adapt or face elimination.
Check out the current price of <a href="https://benzinga.com/quote/amzn">AMZN stock here</a>.
What Happened: Evans wrote on X on Wednesday that Jassy is delivering &#8220;a really simple truth&#8221; to give current Amazon employees time to prepare for job competition driven by AI efficiency gains. &#8220;Amazon, even with new projects, does not expect to keep everyone,&#8221; Evans stated, adding that the company will retain &#8220;the most productive, most valuable people.&#8221;
The former VP, who worked directly with Jassy, characterized the CEO&#8217;s Tuesday blog post as firing &#8220;the starting gun&#8221; on an internal race where employees must prove their AI-resistant value or risk layoffs.
Evans urged workers to identify skills that AI cannot easily replace and invest in capabilities where AI enhances rather than replaces human performance.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Andy Jassy is trying to lay out a really simple truth soon enough to give everyone currently at Amazon a chance to adapt: 1) Amazon, even with new projects, does not expect to keep everyone 2) They are going to keep the best (most productive, most valuable) people 3) Yes,…
&mdash; Ethan Evans (@EthanEvansVP) <a href="https://twitter.com/EthanEvansVP/status/1937970794984051125?ref_src=twsrc%5Etfw">June 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/46107638/mark-zuckerbergs-meta-beats-lawsuit-over-ai-training-on-books-judge-finds-no-meaningful-evidence-on-market-dilution">Mark Zuckerberg&#8217;s Meta Beats Lawsuit Over AI Training On Books, Judge Finds &#8216;No Meaningful Evidence On Market Dilution&#8217;</a>
Why It Matters: Jassy&#8217;s announcement last week revealed <a href="https://www.benzinga.com/markets/tech/25/06/45990634/amazon-ceo-andy-jassys-ai-led-job-cuts-warning-sparks-backlash-as-employee-reportedly-says-its-clearly-part-of-the-plan">Amazon has over 1,000 generative AI services</a> and applications in development. The company&#8217;s AI-driven Alexa+ serves tens of millions of customers globally, while more than 50,000 advertisers used AI capabilities in the first quarter alone. 
Amazon has committed over $100 billion to <a href="https://www.benzinga.com/markets/tech/25/06/45990634/amazon-ceo-andy-jassys-ai-led-job-cuts-warning-sparks-backlash-as-employee-reportedly-says-its-clearly-part-of-the-plan">AI infrastructure investments</a>, including $13 billion for Australia&#8217;s data center expansion through 2029.
Internal employee reactions viewed by Business Insider <a href="https://www.benzinga.com/markets/tech/25/06/45990634/amazon-ceo-andy-jassys-ai-led-job-cuts-warning-sparks-backlash-as-employee-reportedly-says-its-clearly-part-of-the-plan">showed mixed responses across Slack channels</a>. &#8220;There is nothing more motivating on a Tuesday than reading that your job will be replaced by AI in a few years,&#8221; one employee wrote. Others questioned whether senior leadership would face similar cuts, noting Amazon&#8217;s S-team expansion under Jassy.
The workforce warning comes as Amazon froze <a href="https://www.benzinga.com/markets/tech/25/06/45990634/amazon-ceo-andy-jassys-ai-led-job-cuts-warning-sparks-backlash-as-employee-reportedly-says-its-clearly-part-of-the-plan">retail hiring budgets this year</a> while expanding AI capabilities. Jassy previously called AI investments a &#8220;once-in-a-lifetime reinvention of everything we know,&#8221; emphasizing substantial capital requirements for AI chips and data centers.
Evans warned that attacking leadership for delivering &#8220;unpleasant truth&#8221; only encourages delays that lead to &#8220;brutal surprise down the road.&#8221; He advised employees to start transitioning skills immediately, stating, &#8220;Get started or get hurt.&#8221;
AMZN performs strongly on Growth and Quality metrics, with decent Momentum and Value scores. For&nbsp;<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">more insights like this, subscribe</a>&nbsp;to&nbsp;Benzinga Edge Stock Rankings&nbsp;today! <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener"></a>
<figure class="wp-block-image aligncenter size-full is-resized"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="886" height="638" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26042940/image-402.png" alt="" class="wp-image-962820" style="width:416px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26042940/image-402.png 886w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26042940/image-402-300x216.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26042940/image-402-768x553.png 768w" sizes="(max-width: 886px) 100vw, 886px" /></a></figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46109638/microsoft-ceo-satya-nadella-praises-palantirs-fde-model-as-fantastic-insiders-say-its-not-consulting-it-builds-the-product-customers-need">Microsoft CEO Satya Nadella Praises Palantir&#8217;s FDE Model As &#8216;Fantastic&#8217;—Insiders Say It&#8217;s Not Consulting, It Builds &#8216;The Product Customers Need&#8217;</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Markus Mainka / Shutterstock.com

Equities

Markets

AMZN

Amazon CEO Andy Jassy Warns Of AI-Driven Workforce Reduction — AMZN 'Won't Keep Everyone,' Says Ex-VP Ethan Evans In Warning To Employees

Patrick&nbsp;Witt, deputy director of the White House Council on Digital Assets, said Wednesday that the administration is pursuing a &#8220;accumulation plan&#8221; to acquire Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) for the strategic national reserve.
What Happened:&nbsp;During a fireside chat at the Bitcoin Policy Summit in Washington, D.C., Witt emphasized the Trump administration&#8217;s dedication to the leading cryptocurrency.
&#8220;We&#8217;ve&nbsp;already taken some steps with&nbsp;the SBR [Strategic Bitcoin Reserve]. How&nbsp;do we follow that up&nbsp;with an accumulation plan,&#8221; he stated. &#8220;There&#8217;s no shortage of opportunities and things to do.&#8221;
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="The Bitcoin Policy Summit 2025" width="500" height="281" src="https://www.youtube.com/embed/nog5yD9fVhE?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Witt also acknowledged the challenges in implementing these plans, but assured that the team is &#8220;working around the clock&#8221; to realize President Donald Trump&#8217;s vision.
&#8220;The&nbsp;president on down we&#8217;re&nbsp;all committed to Bitcoin. We&nbsp;want to see it thrive.&nbsp;We want this to be&nbsp;the crypto capital of the&nbsp;world,&#8221; he said.
See Also:&nbsp;<a href="https://benzinga.com/crypto/cryptocurrency/25/06/45995223/genius-stablecoin-bill-clears-senate-but-trumps-crypto-profits-loom-over-momentum" target="_blank" rel="noreferrer noopener">GENIUS Stablecoin Bill Clears Senate But Trump's Crypto Profits Loom Over Momentum</a>
Why It Matters:&nbsp;Witt&#8217;s remarks aligned with previous indications from the White House regarding its focus on Bitcoin. In March, Bo Hines, the&nbsp;executive director of the White House Council on Digital Assets, <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44450232/white-house-says-gold-reserves-may-be-used-to-purchase-bitcoin">hinted at the possibility</a> of the U.S. utilizing its gold reserves to acquire more Bitcoin.
Last month, Trump's crypto and AI advisor, David Sacks, said that the path to acquiring Bitcoin for the strategic reserve is ready and it's just a matter of <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45635887/trumps-crypto-advisor-about-us-plans-on-buying-more-bitcoin-it-all-boils-down-to">getting the relevant executive departments "excited</a>." 
Trump signed an executive order to&nbsp;<a href="https://www.benzinga.com/25/03/44183572/trump-establishes-strategic-bitcoin-reserve-funded-by-forfeited-assets-i-made-the-promise" target="_blank" rel="noreferrer noopener">establish</a>&nbsp;a strategic Bitcoin reserve earlier this year. The order allows for the purchase of additional BTC, provided there are no incremental costs to taxpayers.
However, little has come from the executive side since the order was signed. Moreover, some analysts have dubbed the idea of selling gold to accumulate Bitcoin&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44148667/a-benzinga-debate-on-federal-reserve-assets-our-contributors-speak-on-gold-bitcoin" target="_blank" rel="noreferrer noopener">a &#8220;very risky&#8221; prospect</a>.
Price Action:&nbsp; At the time of writing, Bitcoin was exchanging hands at $107,813.32, up 1.08% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/25/06/46109437/anthony-pomplianos-company-may-have-bought-more-bitcoin-than-gamestop-but-michael-saylors-strategy-and-mara-still-reign-supreme">Anthony Pompliano&#8217;s Company May Have Bought More Bitcoin Than GameStop, But Michael Saylor&#8217;s Strategy And MARA Still Reign Supreme</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo: Shutterstock<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" target="_blank" rel="noreferrer noopener"></a>

$BTC

White House Official Says Trump Administration Is Committed To Bitcoin, Hints At 'Accumulation Plan' For Strategic Reserve

Shares of Worthington Steel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) rose sharply in today's pre-market trading as the company reported <a href="https://www.benzinga.com/quote/WS/earnings">stronger-than-expected financial results for the fourth quarter.</a>
The company reported quarterly earnings of $1.05 per share, which beat the analyst consensus estimate of 82 cents per share.
Worthington Steel shares jumped 15.7% to $30.38 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) surged 105.6% to $1.14 in pre-market trading. Vor Bio and RemeGen signed a global license agreement for autoimmune asset Telitacicept, securing $125 million payment and $175 million private placement.</li>
<li>Adial Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) gained 51.2% to $0.3719 in pre-market trading. Adial Pharmaceuticals shares gained 7% on Wednesday after the company announced it secured AD04 production agreements with Cambrex and Thermo Fisher Scientific ahead of its New Drug Application submission to the FDA for the treatment of Alcohol Use Disorder.</li>
<li>MKDWELL Tech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) gained 30% to $0.3061 in pre-market trading.</li>
<li>Baird Medical Investment Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDMD#NASDAQ">BDMD</a>) rose 17.5% to $7.80 in pre-market trading after gaining 4% on Wednesday.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) jumped 17.4% to $8.50 in pre-market trading after falling 17% on Wednesday.</li>
<li>Beeline Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNE#NASDAQ">BLNE</a>) climbed 16.6% to $1.54 in pre-market trading after falling 7% on Wednesday.</li>
<li>Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) gained 14.2% to $12.95 in pre-market trading after dipping 24% on Wednesday.</li>
<li>Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) rose 12.8% to $8.70 in pre-market trading. Altimmune will announce 24-week data from IMPACT Phase 2b trial of Pemvidutide in MASH treatment on June 26.</li>
<li>MillerKnoll, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) gained 10.7% to $19.50 in pre-market trading after the company reported better-than-expected quarterly EPS and sales.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares tumbled 30.2% to $0.5310 in pre-market trading after the company announced a proposed public offering.</li>
<li>Globavend Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) dipped 12.2% to $0.6105 in pre-market trading after dipping 44% on Wednesday.</li>
<li>ZyVersa Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) fell 10.7% to $0.6335 in pre-market trading. ZyVersa Therapeutics, on Wednesday, announced a share purchase agreement for up to $10 million in partnership with Williamsburg Venture Holdings to fund clinical development of Cholesterol Efflux Mediator&#x2122; VAR 200.</li>
<li>GlucoTrack, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) dipped 9.4% to $7.10 in pre-market trading. Glucotrack shares jumped 26% on Wednesday after the company and OneTwo Analytics presented final results of their first-in-human study for a continuous blood glucose monitor, which met all primary and secondary endpoints.</li>
<li>Wag! Group Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) declined 9% to $0.0975 in pre-market trading after gaining 6% on Wednesday.</li>
<li>XCF Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAFX#NASDAQ">SAFX</a>) fell 8.8% to $2.07 in pre-market trading after surging more than 32% on Wednesday.</li>
<li>Portage Biotech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) declined 7.5% to $5.65 in pre-market trading. Portage Biotech shares gained 7% on Wednesday after the company announced it regained Nasdaq compliance.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>) fell 7% to $39.38 in pre-market trading after the company priced its public offering of common stock.</li>
<li>Crescent Biopharma, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBIO#NASDAQ">CBIO</a>) shares fell 6.2% to $16.89 in pre-market trading. Stifel, on Wednesday, initiated coverage on the stock with a Buy rating and announced a price target of $28.</li>
<li>Oriental Rise Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIS#NASDAQ">ORIS</a>) fell 5% to $0.5992 in pre-market trading after dipping around 32% on Wednesday.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

ADIL

BDMD

BLNE

CBIO

GCTK

KTOS

MKDW

MLKN

ORIS

PRTG

RVPH

SAFX

ZVSA

Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket

A widely watched labor market sentiment indicator has dropped to its lowest level since early 2017, excluding the pandemic spike, signaling potential trouble ahead for the U.S. job market.
What Happened: On Wednesday, The Kobeissi Letter shared the results of the recent Conference Board's Consumer Confidence survey, showing that the gap between the percentage of Americans who say jobs are &#8220;plentiful&#8221; and those who say they are &#8220;hard to get&#8221; has shrunk to just 11.1%.
Seen by many economists as a forward-looking signal for labor market strength or weakness, historically, the narrowing of this spread has almost always been followed by a rise in unemployment. The spread is now at its lowest level since 2017, ignoring the spike seen during the COVID-19 pandemic.
See Also: <a href="https://www.benzinga.com/markets/25/06/46013949/people-are-confused-if-houses-arent-selling-why-arent-prices-dropping-thats-insane-one-buyer-says">People Are Confused—If Houses Aren&#8217;t Selling, Why Aren&#8217;t Prices Dropping? &#8216;That&#8217;s Insane,&#8217; One Buyer Says</a>
According to the post, &#8220;It now suggests the unemployment rate could rise to 6.0% in the coming months.&#8221;
For context, the current U.S. unemployment numbers stand at 4.2%, according to <a href="https://www.benzinga.com/25/05/45661563/one-in-four-americans-are-functionally-jobless-the-true-unemployment-metric-thats-raced-to-its-highest-in-months">the latest data</a> from the Bureau of Labor Statistics. As such, these figures show that the labor market is deteriorating faster than the headlines numbers might indicate.
&#8220;The labor market is clearly losing momentum,&#8221; the post says in conclusion.
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">A leading indicator in the US job market suggests higher unemployment rates are ahead: The gap between those saying jobs are "plentiful" and "hard to get" declined to 11.1%, the lowest since early 2017, excluding the pandemic spike. In other words, US consumers&#39; perceptions of… <a href="https://t.co/9cB0aU4fFE">pic.twitter.com/9cB0aU4fFE</a>
&mdash; The Kobeissi Letter (@KobeissiLetter) <a href="https://twitter.com/KobeissiLetter/status/1937887003020034351?ref_src=twsrc%5Etfw">June 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: While the U.S. unemployment report came in steady at 4.2% in May, there are growing concerns that AI is <a href="https://www.benzinga.com/tech/25/05/45613320/ai-is-gutting-entry-level-jobs-and-gen-z-is-paying-the-price-warns-linkedins-aneesh-raman">gutting entry-level jobs</a>, hitting recent Gen Z college graduates the hardest.
On Wednesday, economist Craig Shapiro warned that AI <a href="https://www.benzinga.com/markets/economic-data/25/06/46093421/ai-will-disrupt-25-of-us-jobs-by-2030-and-the-fed-cant-save-them-economist-warns">will disrupt 25% of all jobs</a> by 2030, and there is little to nothing that the Federal Reserve can do to address this issue.
&#8220;AI-driven labor displacement, accelerating in 2025, poses a structural crisis that Federal Reserve rate cuts cannot fix,&#8221; he said.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/46087650/feds-schmid-says-wait-and-see-approach-right-for-rate-policy-as-tariff-fallout-still-unclear">Fed&#8217;s Schmid Says &#8216;Wait-and-See&#8217; Approach Right For Rate Policy As Tariff Fallout Still Unclear</a></li>
</ul>
Photo courtesy: Shutterstock

Economics

US Labor Market Is Flashing Red: 'Plentiful' Versus 'Hard-To-Get' Job Gauge Hits 4-Year Low, Signals Unemployment Could Jump To 6%

IPOs

Julong Holding Limited Prices Initial Public Offering1.25M Class A Common Shares At $4 Per Share, Totaling $5M; Shares To Start Trading On Nasdaq Under "JLHL"

In a move to help companies deal with mounting volatility in the world economy, C.H. Robinson, a global logistics provider managing 37 million shipments annually, is opening its industry-leading Item-level Solutions to all its customers.
Item-level Solutions provide end-to-end visibility and control across inventories and supply chains at the most granular level—by the individual item or SKU. This includes tracking items in motion or at rest, managing orders and inventory with unparalleled precision, and enabling real-time insights for better planning, cost control, and customer service while reducing blind spots. Using C.H. Robinson's Item-level Solutions, users have seen up to 10-30% percent savings in supply-chain-related expenses.
The initiative bundles C.H. Robinson's advanced analytics, tailored solutions, scale and 120 years of hands-on expertise—a unique combination that no other logistics provider in the marketplace can offer. So far, the fully integrated suite with all its competitive advantages has been used predominantly by shippers with the most complex supply chain needs. Now, Robinson is scaling it up to the rest of its global customer base.
The growing need for item-level control in logistics is spurred by continued disruptions since the pandemic. Volumes handled with C.H. Robinson's newest item-level digital purchase order management tools increased almost twenty-fold between 2023 and 2024, and are on track to double again this year. The company also saw a 300% rise in supply chain design projects using item-level data in the last three years.

CHRW

C.H. Robinson Expands Item-Level Solutions to Help Companies Navigate Supply Chain Challenges

Golar LNG Limited (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLNG#NASDAQ">GLNG</a>) announces today the pricing of $500 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2030 (the "Notes"), in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company has also granted the initial purchasers of the Notes a 30-day option to purchase up to an additional $75 million aggregate principal amount of the Notes in connection with the offering. The offering is expected to close on June 30, 2025, subject to the satisfaction of certain customary closing conditions.
The Notes will be senior, unsecured obligations of the Company, bear interest at a rate of 2.75% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, beginning on December 15, 2025, mature on December 15, 2030, and be convertible into the Company's common shares, cash, or a combination of shares and cash, at the Company's election. The conversion rate for the Notes will initially equal 17.3834 common shares per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $57.53 per common share, representing an initial conversion premium of approximately 40% over the volume-weighted average price of the Company's common shares of $41.09 on June 25, 2025 and is subject to adjustment upon the occurrence of certain events.
The Notes will be redeemable, in whole or in part (subject to certain limitations), at our option at any time, and from time to time, on or after December 20, 2028 if the last reported sale price of our common shares has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.
If we undergo a fundamental change (as defined in the indenture governing the Notes), holders may require us to purchase the Notes in whole or in part for cash at a fundamental change purchase price equal to 100% of the principal amount of the Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date.
The Company will use the net proceeds from the sale of the Notes (including any notes sold pursuant to the initial purchasers' option to purchase addition Notes, if exercised) to repurchase 2.5 million of the Company's common shares in connection with the offering of the Notes and for general corporate purposes, which may include, among other things, future growth investments including a contemplated fourth FLNG unit, MKII FLNG conversion costs, FLNG Hilli redeployment costs, repaying indebtedness, and funding working capital and capital expenditures.

Offerings

Buybacks

GLNG

Golar LNG Prices $500M Convertible Senior Notes Offering to Fund Share Buybacks and Future Growth

Future Fund LLC's managing director, Gary Black, thinks that investors should stop focusing on Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Robotaxi's autonomous driving when compared to Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Waymo when it comes to valuation.
What Happened: In response to a social media reply on X questioning Robotaxi's autonomy, investor Gary Black said Wednesday that &#8220;investors need to stop focusing on Tesla vs. Waymo efficacy.&#8221;
He then added that Waymo had recently conducted an equity raise at a "$45 billion valuation." The investor then shared how Robotaxi's perceived value, with the assumption that Tesla&#8217;s stock value is "60x P/E (vs 25-30% long-term growth) is $500B."
Black said that investors are valuing Robotaxi because of Elon Musk's EV giant's "far greater scalability and profitability." Musk has shared on multiple occasions that most Tesla vehicles can serve as Robotaxis thanks to FSD or Full Self-Driving.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Investors need to stop focusing on <a href="https://twitter.com/search?q=%24TSLA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$TSLA</a> vs Waymo efficacy. Waymo recently did an equity raise at $45B valuation. The implied value of Robotaxi assuming the rest of TSLA is valued at 60x P/E (vs 25-30% long-term growth) is $500B. The market is putting a multiple of value on TSLA… <a href="https://t.co/Q10DHCPqmh">https://t.co/Q10DHCPqmh</a>
&mdash; Gary Black (@garyblack00) <a href="https://twitter.com/garyblack00/status/1937902585349906457?ref_src=twsrc%5Etfw">June 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The comments come in as the investor had earlier called out a <a href="https://www.benzinga.com/markets/tech/25/06/46088826/gary-black-calls-out-lack-of-constructive-feedback-on-teslas-robotaxi-launch">‘lack of constructive feedback'</a> for the company's Austin launch. Black also rubbished claims of Tesla's Robotaxi being years ahead of competitors as "nonsense."
Tesla's Robotaxi launch in Austin on Sunday has garnered a lot of attention within the auto industry, with experts like Wedbush Securities' Dan Ives praising the launch as a <a href="https://www.benzinga.com/markets/tech/25/06/46049232/dan-ives-hails-very-impressive-robotaxi-ride-in-austin-predicts-55-upside-for-tesla-stock-as-golden-age-begins">golden age for Tesla</a> and Alex Potter, an analyst with investment firm Piper Sandler, said that the launch could <a href="https://www.benzinga.com/markets/tech/25/06/46108079/tslas-robotaxi-could-disrupt-auto-industry-says-piper-sandler-contrasts-goldmans-cautious-view-tesla-will-likely-win" target="_blank" rel="noopener">disrupt</a><a href="https://www.benzinga.com/markets/tech/25/06/46108079/tslas-robotaxi-could-disrupt-auto-industry-says-piper-sandler-contrasts-goldmans-cautious-view-tesla-will-likely-win"> the industry</a>. 
However, the launch has also invited a lot of scrutiny, with NHTSA saying it&#8217;s reviewing incidents where the Robotaxis committed <a href="https://www.benzinga.com/markets/tech/25/06/46067027/tesla-robotaxi-faces-nhtsa-scrutiny-over-traffic-violations-during-austin-launch">possible traffic violations</a> like speeding as well as driving in the wrong lane.
The EV giant also faces a <a href="https://www.benzinga.com/markets/tech/25/06/46068107/elon-musks-tesla-faces-wrongful-death-lawsuit-over-model-s-crash-which-claimed-3-lives-plaintiffs-call-cars-design-defective-and-unreasonably-dangerous">wrongful death lawsuit</a> over a 2024 crash in New Jersey when a Tesla Model S carrying 3 passengers veered off the road, adding to questions over the FSD technology&#8217;s readiness to be deployed into the real world.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="203" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26042829/TSLA-JUN-26-2025-1-1024x203.jpg" alt="" class="wp-image-962815" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26042829/TSLA-JUN-26-2025-1-1024x203.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26042829/TSLA-JUN-26-2025-1-300x59.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26042829/TSLA-JUN-26-2025-1-768x152.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26042829/TSLA-JUN-26-2025-1-1536x304.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26042829/TSLA-JUN-26-2025-1.jpg 1561w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Tesla scores well on Momentum, Quality and Growth metrics, but offers poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge Stock Rankings</a> today!
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46087914/teslas-europe-sales-slide-for-5th-straight-month-elon-musk-led-ev-giants-market-share-shrinks-to-1-3">Tesla&#8217;s Europe Sales Slide For 5th Straight Month: Elon Musk-led EV Giant&#8217;s Market Share Shrinks To 1.3%</a></li>
</ul>
Photo courtesy: Shutterstock

GOOG

GOOGL

TSLA

Gary Black Weighs In On Tesla Vs Waymo Debate, Says Investors Need To Stop Focusing On Efficacy

Health Care

Press Releases

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Analyst Ratings

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

VYNE Therapeutics to Participate in March Investor Conferences

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

VYNE Therapeutics Provides Update on VYN202 Program

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

Comments

VYNE Therapeutics

ニュース

最新ニュース VYNE Therapeutics (NASDAQ:VYNE) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル